Thus, treatment by the simultaneous inhibition of NF-κB and IL-6/STAT3 signaling is a possible therapeutic strategy to improve the response to chemotherapy and radiation in prostate cancer. The gene discussed is STAT3; the disease is prostate carcinoma.